Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Osteoarthritis (OA) Pain

PHASE2CompletedINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
Pain
Interventions
DRUG

ZR-02-01 Fentanyl Transdermal Matrix Patch

Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period.

DRUG

Placebo Patch

Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period

Trial Locations (13)

10003

Beth Israel Medical Center, New York

10022

Analgesic Development Ltd., New York

32114

Radiant Research, Daytona Beach

33614

Tampa Medical Group, Tampa

34474

Ocala Rheumatology, Ocala

70119

New Orleans Center for Clinical Research, New Orleans

85023

Arizona Reserach Center, Phoenix

85029

Redpoint Research, Phoenix

91786

Boling Clinical Trials, Upland

92101

Sharp Rees-Stealy Medical Group, San Diego

92108

San Diego Arthritis Medical Clinic, San Diego

02115

Pain Trials Center - Brigham & Women's Hospital, Boston

02720

Phase III Clinical Trials, Fall River

All Listed Sponsors
lead

ZARS Pharma Inc.

INDUSTRY

NCT00108771 - Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Osteoarthritis (OA) Pain | Biotech Hunter | Biotech Hunter